CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology

Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.